CC BY-NC-ND 4.0 · World J Nucl Med 2022; 21(01): 062-064
DOI: 10.1055/s-0042-1744200
Case Report

Tc-99m-PSMA-SPECT/CT Is Superior to Tc-99m-MDP-SPECT/CT in the Staging of Prostatic Cancer with Osseous Metastases after External Beam Radiotherapy

Knut Liepe*
1   Department of Nuclear Medicine, Klinikum Frankfurt (Oder), Frankfurt, Germany
,
Marcel Baehr*
1   Department of Nuclear Medicine, Klinikum Frankfurt (Oder), Frankfurt, Germany
› Author Affiliations

Abstract

In the reported patient with advanced prostate cancer, a bone scan showed a false positive finding in thoracic vertebrae bone metastasis after external beam radiotherapy 2 months ago. An additional Tc-99m-prostate-specific membrane antigen scan showed a negative finding, although nonirradiated iliac bone metastasis was concordantly positive in both scans. The decrease in prostate-specific antigen-level from 156.6 ng/mL to 2.3 ng/mL indicates a strong effect of treatment, hence supporting false positivity in bone scan by flare phenomenon.

Declarations

The authors declare that no funding was applicable.


The authors declare that no conflicts of interest/competing interests were applicable. The authors declare that no ethics approval was necessary. The authors declare that no consent to participate was necessary. The authors have consent of publication of their data. The used data and material are available and can be requested. The licenses of used software are available.


* The two authors contributed equally to this article and share the first authorship.




Publication History

Article published online:
11 March 2022

© 2022. World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Rii J, Sakamoto S, Yamada Y. et al. Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients. Prostate 2020; 80 (11) 850-858
  • 2 Witkowska-Patena E, Mazurek A, Dziuk M. 68Ga-PSMA PET/CT imaging in recurrent prostate cancer: where are we now?. Cent European J Urol 2017; 70 (01) 37-43
  • 3 Hofman MS, Lawrentschuk N, Francis RJ. et al; proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395 (10231): 1208-1216
  • 4 Messiou C, Cook G, deSouza NM. Imaging metastatic bone disease from carcinoma of the prostate. Br J Cancer 2009; 101 (08) 1225-1232